OrbiMed

Providing tailored financing solutions and global team resources to help build
world-class healthcare companies.

From biopharmaceuticals to medical devices, digital health, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer, and more productive lives.

We have been investing globally for over 25 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 130 distinguished scientific, medical, investment, and other professionals manages approximately $17 billion across public and private company investments worldwide.

How We Invest

Meet Our Companies Driving Healthcare Innovation

Messenger RNA targeting to create life-saving therapeutics

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

Learn More

Pushing targeted oncology drug discovery to new heights

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

Learn More

Revolutionizing Cancer Care

With a primary focus on cancer, Caris has built a market-leading portfolio of precision medicine tools that have helped more than half a million cancer patients worldwide. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease.

Learn More

Redefining Immunology and Inflammation with Precision

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.

Learn More

A Global Leader in Antibody and ADC Oncology Therapies

Biokin is a clinical-stage company developing innovative ADCs, bi-specific, and multi-specific antibodies for the treatment of cancers. By targeting multiple signaling pathways, Biokin is seeking to overcome the insufficient anti-tumor responses typical of existing mono-antibody therapies.

Learn More

Taking a leading approach to tackle the complexities of cancer

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs).

Learn More

View All